In November 2022, Repertoire Immune Medicines pulled the plug on two clinical-stage programs. RPTR-147. RPTR-168.

Both cell therapies. Both terminated. One Phase 1 trial enrolled 23 patients and ended. Another stopped at 7.

At the time, it looked like a death knell…yet another immunology biotech running out of runway.

Three and a half years later, Repertoire has dosed the first patient in a Phase 1/2 trial of RPTR-1-201, a TCR bispecific that will be tested across nine tumor types including colorectal, NSCLC, HNSCC, TNBC, pancreatic, cervical, gastric, esophageal, and bladder.

This doesn’t really seem like a desperate pivot – its more like a phoenix rising from the ashes.

The story of what happened in between is worth telling.

Repertoire didn’t abandon the science when the cell therapies failed.

They doubled down on their DECODE platform, which uses sequencing, computational biology, and machine learning to map T cell receptor-antigen pairs from actual patient samples. The idea is that if you know exactly which TCRs are recognizing which tumor epitopes in real patients, you can engineer better immune medicines than anyone trying to do this synthetically.

Well, apparently the industry noticed because in April 2024, Bristol Myers Squibb partnered with Repertoire on tolerizing vaccines for autoimmune disease. That same month, Genentech came in with $35 million upfront and up to $730 million in milestones.

Two of the biggest pharma names in immunology validating a platform at the same time. That doesn’t happen by accident.

Now the platform has produced its first clinical asset.

RPTR-1-201 is designed as an off-the-shelf TCR bispecific molecule. One arm engineered to recognize a tumor-specific epitope via a TCR. The other arm an anti-CD3 domain that recruits and activates T cells to kill the tumor cell.

Pretty standard.

The trial design is what catches my eye because I tried to find the pMHC target and couldn’t so I thought I’d check the indication for a clue…and…its a basket??

A nine-tumor basket…

Most first-in-human TCR bispecifics pick one or two indications and try to show depth before expanding.

Repertoire is going wide, betting that their platform has identified a shared antigen or TCR signature that cuts across tumor types. They’re also running combinations with anti-PD-1 alongside monotherapy from the jump – which does make sense. I’ve been seeing more and more of this lately.

If the target is what I think it is — something tumor-associated but broadly expressed across epithelial cancers — this isn’t really nine trials. It’s one platform thesis being stress-tested across nine patient populations at once.

The primary endpoints are conservative: safety, tolerability, early antitumor activity. Which is fine for first-in-human. But the real question is whether any of the nine tumor types produces a signal clean enough to pick an expansion cohort.

That’s what Repertoire needs to show in 2026 and 2027 to keep the platform story alive.

With more than $350 million raised over the company’s history and two of the biggest deals in autoimmune and oncology validating the platform, Repertoire has the runway to find out. But the post-2022 narrative lives or dies on whether RPTR-1-201 produces responses that the discontinued programs couldn’t.

First readouts from the dose escalation could land in late 2026 or early 2027. That’s when we find out if the pivot worked.